gdc
FDA Approvals, News & UpdatesLung CancerNewsworthy

FDA Approved Opdivo for Metastatic Small-Cell Lung Cancer

October 2018 Vol 4 No 5

In August 2018, the FDA approved the immunotherapy Opdivo (nivolumab; from Bristol-Myers Squibb) for the treatment of patients with metastatic (spreading) small-cell lung cancer that progressed after platinum-based chemotherapy and at least 1 other therapy.

Opdivo was previously approved by the FDA for patients with non–small-cell lung cancer, the most common type of lung cancer. This new approval makes this immunotherapy also available for patients with small-cell lung cancer, which has fewer treatment options.

This approval was based on results from a clinical trial of 109 patients with or without PD-1 expression who had metastatic small-cell lung cancer that progressed after chemotherapy and at least 1 other therapy.

Overall, in 13 patients with small-cell lung cancer, the cancer responded to treatment with Opdivo, and the responses lasted between 6 months to more than 18 months. This new approval for Opdivo now offers patients with small-cell lung cancer access to immunotherapy, an important addition to the treatment options available for patients with this type of lung cancer.

The side effects with Opdivo in this study were similar to those seen in other studies, and 10% of patients discontinued treatment because of side effects.

Recommended For You
CholangiocarcinomaFDA Approvals, News & Updates
Pemazyre First Therapy Approved for Cholangiocarcinoma with FGFR2 Biomarker
On April 17, 2020, the FDA approved Pemazyre (pemigatinib; from Incyte)—an oral inhibitor of FGFR gene fusions or rearrangements 1, 2, and 3— for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma and the biomarker FGFR2 gene fusions.
Breast CancerFDA Approvals, News & Updates
Approved for Breast Cancer and HER2 Biomarker
On April 17, 2020, the FDA approved Tukysa (tucatinib; from Seattle Genetics), a kinase inhibitor, for use with chemotherapy (trastuzumab and capecitabine) for the treatment of adults with unresectable (cannot be removed by surgery) advanced or metastatic (spreading) HER2-positive breast cancer, after 1 or more previous treatments. Tukysa blocks the kinase enzyme, thereby blocking the growth of cancer cells.
Lung Cancer
Biomarkers in Lung Cancer: What Are They and Why Do They Matter?
By Upal Basu Roy, PhD, MPH
Lung cancer continues to be the second most common cancer in the United States and the leading cause of cancer-related death for men and for women. Lung cancer is often diagnosed in a later stage, when treatment may be more challenging than when the cancer is detected early.
Lung Cancer
Treatment of Non–Small-Cell Lung Cancer: A Guide for Patients
By Blanca A. Ledezma, MSN, NP, Edward B. Garon, MD
In the second article of this 4-part series, the authors present an overview of the current treatment landscape for NSCLC, including a description of the most often used treatments and common questions that patients can ask their providers.
Last modified: October 27, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country